"Phoenix from the ashes" Swiss company becomes a stock market rocket - this is the reason
From problem child to stock market star: Idorsia's shares have gone through the roof in just six months - thanks to a new blood pressure medication and renewed confidence in the Swiss biotech company.
No time? blue News summarizes for you
- Idorsia's share price has quadrupled since April, making it one of the biggest stock market winners in Switzerland.
- The reason for this is the EU approval of the new blood pressure medication Tryvio, which has raised high hopes.
- Despite its success, the company remains loss-making for the time being - the quarterly figures at the end of October should show whether the recovery is bearing fruit.
The crash was deep - the comeback spectacular. The share price of Basel-based biotech company Idorsia has quadrupled since spring 2025. While the share price was just under one franc at the beginning of April, it was already at 4.68 francs on October 7.
This makes Idorsia one of the biggest stock market winners in recent months. In the third quarter alone, the share price rose by 85 percent - the best performance in the Swiss Performance Index (SPI).
The "NZZ" also devoted a report to Idorsia this week - it speaks of its rise "like a phoenix from the ashes". The company's market capitalization is back above one billion Swiss francs, having plummeted to around 150 million Swiss francs at the beginning of the year.
Blood pressure and new sleeping pill
The most recent jump in the share price came after the EU approval of the blood pressure medication Aprocitentan. As reported by several financial portals, the share gained over 15 percent in early trading following the news. The active ingredient - marketed under the name Tryvio - is the first new class of active ingredients to treat therapy-resistant high blood pressure in almost 40 years. The US Food and Drug Administration (FDA) had already given the green light in March.
In addition to Tryvio, Idorsia is relying on the sleeping pill Quviviq, which was launched in China in September. Both drugs should finally lead Idorsia into the profit zone. However, analysts remain cautious. The next quarterly figures on October 30 are seen as a crucial test of whether the recovery on the stock market is also reflected in business.
Idorsia used to belong to Actelion
Idorsia was created in 2017 from Actelion's research department after the pharmaceutical company was sold to Johnson & Johnson. Founders Jean-Paul and Martine Clozel started out with great ambitions.
However, the past few years have been tough: the company had to cut hundreds of jobs and changed management several times. Since July, Srishti Gupta has been at the helm - she is to lead the new start.
As the NZZ writes, Idorsia is also benefiting from the comeback of the biotech sector. After difficult years, investor confidence is returning. Lower interest rates and new takeovers in the pharmaceutical sector are providing fresh impetus. Nevertheless, the newspaper warns that biotech remains a risky business, as only a few companies will manage to establish their drugs on the market in the long term.
